Urinary Bladder Neoplasms research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
This study compares a new treatment, TAR-200, with standard chemotherapy for a type of bladder cancer that has returned after initial treatment. It's for people who can't or won't have surgery to remove their bladder.
United States · Argentina · Belgium - recruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
United States · Argentina · Belgium - recruitingPHASE1, PHASE2
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
This study is testing a new way to deliver a bladder cancer drug, Erdafitinib, directly into the bladder. It's for people with certain types of bladder cancer. Researchers want to find the best dose and see how well it works to treat cancer and reduce side effects.
United States · Canada · Germany - recruitingPHASE3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
This study looks at a new treatment called TAR-210 for a type of bladder cancer. It compares TAR-210 with standard chemotherapy to see which is better at keeping the cancer away.
United States · Argentina · Austria